Helus Pharma Appoints Michael Halstead as Chief Executive Officer
Helus Pharma appointed Michael Halstead as Chief Executive Officer, effective immediately, bringing 25 years of industry experience from his previous role as President of Intra-Cellular Therapies. Mr. Halstead previously led the commercialization of CAPLYTA and Intra-Cellular's $14.6 billion sale to Johnson & Johnson, expertise he will apply as Helus approaches the Q4 2026 topline data readout for its Phase 3 APPROACH study of HLP003.
Key figures
- Drug Name
- HLP003
- Phase Of Trial
- Phase 3
- Patents granted
- >100
- Patent applications
- >350
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.